Neurodegenerative Disorders

Despite a diverse array of clinical manifestations and affected genes, many of the common neurodegenerative disorders share a similar molecular mechanism. Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and prion disease are each characterized by the aggregation of mutated or misfolded proteins into amyloid inclusion bodies. Aggregation results when the accumulation of misfolded proteins exceeds the cell's ability to eliminate them via the ubiquitin-proteasome degradation pathway. Some evidence suggests that these inclusions may represent a cellular defense mechanism intended to sequester toxic oligomers or to induce autophagic elimination of the diseased proteins. Effective future strategies for treatment of these neurodegenerative disorders rely on the understanding of the basic pathways affected in these disorders.

Disease	Type of Aggregation	Cellular Localization	Factor Involved	Brain Region Affected
Alzheimer's Disease (AD)	Neuritic Plaques	Extracellular	Amyloid beta peptide	Cortex, hippocampus, basal forebrain, brain stem
Alzheimer's Disease (AD)	Neurofibrillary tangles	Intracellular	Hyperphosphorylated Tau	Cortex, hippocampus, basal forebrain, brain stem
Parkinson's Disease (PD)	Lewy Body	Intracellular (Cytoplasm)	α-Synuclein	Substantia nigra, cortex, locus ceruleus, rephe (dopaminergic neurons)
Huntington's Disease (HD)	Intranuclear inclusions & cytoplasmic aggregates	Intracellular	Huntingtin with polyglutamate expansion	Striatum, basal ganglia, cortex, others
Amyotrophic Lateral Sclerosis (ALS)	Bonina bodies and axonal spheroids	Intracellular (Cytoplasm)	Various ALS genes	Spinal motor neurons and motor cortex
Prion Disease	Amyloid Plaque	Intracellular & Extracellular	Prion protein	Cortex, brain stem, thalamus, cerebellum, other

GeneTex proudly offers an excellent catalog of high-quality antibodies to study the processes involved in neurodegenerative disorders, the majority of which are validated for multiple applications. Please view the table below of selected antibodies and consider whether they can help accelerate your research.

Alzheimer's Disease

beta amyloid (1-42) antibody-Conformation Specific (GTX134510)

APP antibody
(GTX101336)

Apolipoprotein E antibody (GTX101456)

Parkinson's Disease (PD)

alpha Synuclein antibody (GTX112799)

PGP9.5 antibody (GTX109637)

LRRK2 antibody (GTX113065)

Huntington’s Disease (HD)

Huntingtin antibody (GTX132433)

HIP1 antibody
(GTX131449)

BDNF antibody
(GTX132621)

Amyotrophic Lateral Sclerosis (ALS)

C9orf72 antibody
(GTX632041)

SOD1 antibody
(GTX100554)

TDP43 antibody
(GTX114210)

Prion Disease

Prion Protein/PRP antibody (GTX101063)

Grp58/ERp57 antibody
(GTX113719)

Grp78 antibody
(GTX113340)

See All Related Products

Literature

Brochure - Cited Antibodies

Download the latest version of GeneTex's Cited Antibodies brochure.

Literature

Flyer-Neuroscience

Download the latest version of GeneTex's Neuroscience flyer.

Newsletter

Recombinant Influenza A & B Virus Antibodies for Lateral Flow Assay

Influenza A & B Virus Antibodies (IVD grade)

Newsletter

GeneTex Introduces Recombinant Monoclonal Iba1 Antibody

GeneTex's Iba1 recombinant antibody is suitable for IHC staining and WB.

Literature

Flyer - Cited Antibodies

Download the latest version of GeneTex's cited antibodies flyer.

Newsletter

Independent Knockout Validation of C9ORF72 Antibodies

Independent Knockout Validation of C9ORF72 Antibodies for the research of Amyotrophic lateral sclerosis.

Newsletter

Is ApoE the piece to complete the puzzle of Alzheimer’s disease?

ApoE was identified as a major checkpoint inhibitor of the classical complement cascade, and involved in a possible unifying mechanism underlying Alzheimer’s disease, atherosclerosis, and potentially other inflammatory diseases.

Literature

Flyer - Neurotransmission

Download the latest version of GeneTex's Neurotransmission flyer.

Newsletter

Neurodegeneration: A "Vicious Cycle" Involving Mitochondria, Glia, and Neuronal Death

A "Vicious Cycle" Involving Mitochondria, Glia, and Neuronal Death

Newsletter

Soluble TREM2 is associated with clinical progression of Alzheimer’s disease.

A recent study by Ewers et al. reported that increased soluble TREM2 measured in cerebrospinal fluid was associated with lower rates of cognitive and clinical decline and progression in people with AD.

Newsletter

Clinical trials targeting alpha-synuclein protein in Parkinson’s disease

α-synuclein has become a major therapeutic target in PD. Multiple clinical trials are ongoing.

Literature

Pamphlet - Recombinant Active Proteins

Download the latest version of GeneTex's Recombinant Active Proteins Pamphlet.

Literature

Brochure - World Class Validated Antibodies

Download the latest version of GeneTex's World Class Validated Antibodies brochure.

Literature

Flyer - Neuroinflammation

Download the latest version of GeneTex's Neuroinflammation flyer.

Articles

beta Amyloid

GeneTex’s “beta-Amyloid (1-42) antibody – Conformation-Specific” can specifically detect amyloid plaques in the Alzheimer's Disease brain by IHC-P analysis. The superior specificity and sensitivity of this antibody were confirmed by dot blot, ELISA and side-by-side IHC-P comparison with competitor's.

Literature

Pamphlet - Neuroscience Research

Download the latest version of GeneTex's neuroscience research pamphlet.

Literature

Flyer - Amyotrophic Lateral Sclerosis

Download the latest version of GeneTex's amyotrophic lateral sclerosis flyer.

Literature

Poster - Neurodegenerative Disorders

Download the latest version of GeneTex's neurodegenerative disorders poster.

Literature

Flyer - Neurodegenerative Disorders

Download the latest version of GeneTex's neurodegenerative disorders flyer.

Literature